Medtide Inc. logo

Medtide Inc. (FQ2)

Market Closed
11 Aug, 20:00
XFRA XFRA
2. 20
+0.02
+0.9174%
328.98M Market Cap
- P/E Ratio
- Div Yield
200 Volume
- Eps
2.18
Previous Close
Add Transaction
Day Range
2.2 2.22
Year Range
2.08 4.47
Want to track FQ2 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

FQ2 closed today higher at €2.2, an increase of 0.9174% from yesterday's close, completing a monthly decrease of -8.3333% or -€0.2. Over the past 12 months, FQ2 stock lost -27.6316%.
FQ2 is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XFRA (EUR).

FQ2 Chart

Medtide Inc. (FQ2) FAQ

What is the stock price today?

The current price is €2.20.

On which exchange is it traded?

Medtide Inc. is listed on XFRA.

What is its stock symbol?

The ticker symbol is FQ2.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 328.98M.

Has Medtide Inc. ever had a stock split?

No, there has never been a stock split.

Medtide Inc. Profile

- Industry
- Sector
Dr. Qi Xu CEO
XFRA Exchange
- ISIN
China Country
566 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Medtide Inc. is a cutting-edge biotechnology and medical research firm that specializes in comprehensive contract research, development, and manufacturing services. With a strong emphasis on peptide-based therapeutics, the company operates as both a contract research organization (CRO) and a contract development and manufacturing organization (CDMO). This dual role allows Medtide Inc. to offer a full spectrum of services that support clients throughout the entire drug development process, spanning early-stage drug discovery and preclinical research to clinical development and large-scale commercial production.

Utilizing proprietary technology platforms such as OmniPeptSynth and PeptiConjuX, Medtide Inc. achieves advanced peptide synthesis, formulation, and impurity screening. The company's expertise is particularly focused on the development of innovative peptides, including glucagon-like peptide-1 (GLP-1) analogs, which hold significant importance for treating metabolic and endocrine disorders. Serving a diverse global client base across the United States, China, Europe, Japan, South Korea, and Australia, Medtide Inc. plays a crucial role in accelerating the development pipeline for pharmaceutical and biotechnology firms while contributing to advancements in healthcare and therapeutic innovation.

Products and Services

  • Contract Research Organization (CRO) Services

    Medtide Inc. provides a comprehensive range of CRO services, which include support for drug discovery and preclinical research. This service is designed to help clients navigate the complexities of early-stage drug development, ensuring that effective lead candidates are identified and optimized for further development.

  • Contract Development and Manufacturing Organization (CDMO) Services

    The CDMO services offered by Medtide Inc. encompass the development and manufacturing of active pharmaceutical ingredients (API). This not only includes small-scale production for clinical trials but also extends to large-scale commercial manufacturing, aligning with regulatory standards and client specifications.

  • Peptide Synthesis with OmniPeptSynth

    Through the OmniPeptSynth platform, Medtide Inc. enables advanced peptide synthesis that facilitates the creation of complex peptide structures. This proprietary technology enhances efficiency and yields in the synthesis process, which is vital for the development of high-quality therapeutics.

  • Peptide Formulation Development

    Medtide Inc. specializes in the formulation of peptide-based therapeutics, tailoring solutions to maximize bioavailability and stability. This service ensures that the peptides are effectively delivered and perform optimally in clinical settings.

  • Impurity Screening

    Medtide Inc. incorporates robust impurity screening protocols in its peptide synthesis and production processes. This critical quality control measure helps in identifying and minimizing impurities, ensuring that the final product meets regulatory standards and is safe for patient use.

  • Clinical Development Support

    Medtide Inc. offers extensive support for clinical development, which includes planning and execution of clinical trials. This service assists clients in navigating regulatory requirements and achieving timely approvals for their peptide therapeutics.

Contact Information

Address: No. 69, 12 Street
Phone: 86 517 86737118